Engineer drug candidates with the lowest risk of failure in the critical latter stages of drug development. Our lead optimization solutions reduce off-target activity through improved selectivity, enhance potency, and improve the chemical and metabolic properties of the lead compound for better in vivo pharmacodynamics and pharmacokinetics.
We also offer informatics software applications that help you manage chemical structures and their associated data and properties in an efficient and chemically intelligent way.
Target-based drug discovery requires a hypothesis on the mechanism of action of the disease, which requires the identification a druggable target. This compound-first approach is focused on a drug target, a gene product that provides a starting point for invention of a therapeutic which modulates its expression, function, or activity. It often starts with large biochemical screens against the purified target, overexpressed target in a cell line or other molecular modifications to follow compound interaction.
In phenotypic drug discovery, compounds are identified without knowledge of or bias toward a specific molecular target. This agnostic or mechanism-first approach uses biological assays with translational biomarkers as functional readouts. Phenotypic testing requires a relevant biological model of the disease, for example cell lines showing the disease phenotype or patient-derived cells. Compounds are selected for further characterization based on their ability to revert the disease phenotype to the healthy phenotype.
